Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care by Savic, Sinisa et al.
Savic et al. All Asth Clin Immun  (2015) 11:21 
DOI 10.1186/s13223-015-0088-7
RESEARCH
Retrospective case note review 
of chronic spontaneous urticaria outcomes 
and adverse effects in patients treated 
with omalizumab or ciclosporin in UK secondary 
care
Sinisa Savic1, Alexander Marsland2, David McKay3, Michael R Ardern‑Jones4, Tabi Leslie5,6, Olivier Somenzi7, 
Laura Baldock8 and Clive Grattan6,9*
Abstract 
Background: Omalizumab is approved in the UK as add‑on treatment for chronic spontaneous urticaria (CSU) in 
patients with inadequate response to H1‑antihistamines. Ciclosporin is an established but unlicensed 3rd line option 
for CSU. Two parallel retrospective observational studies were conducted to describe outcomes of treatment and 
adverse events with omalizumab or ciclosporin for CSU treatment.
Methods: Data from UK specialist centres prescribing omalizumab (five centres) or ciclosporin (three centres) in CSU 
patients were collected from hospital records by clinical staff and pooled for analysis.
Results: Forty‑six patients prescribed omalizumab and 72 patients prescribed ciclosporin were included. Twenty‑two 
(48%) omalizumab‑treated patients had paired Urticaria Activity Scores (UAS7), showing a 25.4 point improvement 
during treatment (P < 0.0001). Paired Dermatology Life Quality Index (DLQI) was available in 28 (61%) omalizumab‑
treated and 17 (24%) ciclosporin‑treated patients. At least a 75% improvement in DLQI score was observed in 79% of 
omalizumab‑treated and 41% of ciclosporin‑treated patients, and 65% of omalizumab‑treated patients had complete 
resolution of their quality‑of‑life impairment (DLQI 0–1) versus 21% of ciclosporin‑treated patients. Clinician com‑
ments reported symptom clearance in 15/36 (42%) omalizumab‑treated and 10/60 (17%) ciclosporin‑treated patients. 
Proportions of patients with adverse events were similar but those for omalizumab resembled CSU symptoms, mak‑
ing causality assignment difficult, whereas those for ciclosporin were consistent with its known adverse effect profile.
Conclusions: Validated patient‑reported measures of disease severity and quality of life should be used routinely 
in CSU management. Based on clinician comments and DLQI scores, symptoms and quality of life showed a greater 
improvement in the omalizumab‑treated cohort than in the ciclosporin‑treated cohort.
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Background
In chronic spontaneous urticaria  (CSU), non-sedating 
H1-antihistamines are the treatment of first choice, aim-
ing for complete symptom resolution [1, 2]. However, 
treatment with licensed doses relieves symptoms effec-
tively in fewer than 50% of patients [3]. In cases of 
non-response, recent European guidelines recommend 
increasing H1-antihistamine dose up to four times the 
licensed dose [1], but approximately one-third of patients 
remain antihistamine resistant [4]. The recommended 
treatment options in patients unresponsive to high-
dose H1-antihistamines are ciclosporin, omalizumab 
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or montelukast [1]. Other strategies adopted in clini-
cal practice include a change of H1-antihistamine, using 
a combination of H1- and H2-antihistamines, or addi-
tion of dapsone or methotrexate [1]. Although sup-
ported by clinical guidelines and some clinical studies, 
all second and third-line options, with the exception of 
omalizumab, are unlicensed for CSU. Omalizumab is a 
recombinant humanized monoclonal anti-IgE antibody 
which binds to the Fc region of IgE. By sequestering free 
IgE, it may also indirectly downregulate FcRI receptors 
on mast cells and basophils, reducing histamine release 
potential and hence CSU symptoms [5], however the 
specific mode of action of omalizumab in CSU is cur-
rently unknown. In 2014 omalizumab (300 mg by subcu-
taneous injection every 4 weeks) was licensed as add-on 
therapy for the treatment of CSU in adult and adolescent 
(12  years and above) patients with inadequate response 
to H1-antihistamine treatment [6], following studies 
which demonstrated its efficacy and safety in this group 
of patients [7–9].
The aim of this investigation was to gather UK real 
world evidence of third-line treatment options for CSU 
to facilitate clinical treatment decision making. We con-
ducted two parallel multicentre retrospective case note 
review studies. In the first study we reviewed patients 
treated with omalizumab for CSU and in the second, par-
allel study, we reviewed patients treated with ciclosporin 
for CSU. We report here the results of both studies, 
describing the characteristics of patients treated, and the 
dosing patterns, outcomes and adverse events associated 
with these treatments.
Methods
Study sites were identified through clinicians with a spe-
cialist interest in CSU, treating patients in dermatology 
or immunology services. The omalizumab study was 
conducted in five UK specialist tertiary centres (4 Der-
matology, 1 Immunology). The ciclosporin study was 
conducted in 3 of these 5 centres (2 Dermatology, 1 
Immunology).
Patients’ clinical records were reviewed retrospec-
tively by the responsible clinicians and ethical approval 
for both studies was covered by UK regulations for ret-
rospective medical records review [10]. Research govern-
ance approval was obtained for study conduct at each 
participating centre.
For the present investigation, the omalizumab study 
comprised consecutive eligible patients first prescribed 
omalizumab for any form of CU (n  =  55) between 
19/10/09 and 14/02/14 without selective sampling and 
we present here those with CSU (n = 46). The eligibility 
period was pre-licence and omalizumab was accessed via 
individual funding requests (IFR). The ciclosporin study 
included consecutive adult patients who received ciclo-
sporin for CSU treatment between 8/08/08 and 31/12/12. 
Patients with co-existing asthma or atopic eczema were 
excluded to avoid uncertainty over the indication for pre-
scribing ciclosporin.
All clinical staff were trained in the study requirements 
and a standardised data collection form and data collec-
tion guidelines were used to ensure consistency of meth-
odology across all centres for each study.
The dataset for each study was collected by members of 
the clinical team from patients’ clinical records, includ-
ing paper case-notes and electronic hospital databases. 
Patient and disease baseline characteristics [age, sex, 
symptoms and severity of CSU, weekly Urticaria Activity 
Score (UAS7), Dermatology Life Quality Index (DLQI) 
score, presence of angioedema and severity score, weight, 
symptom onset and diagnosis dates, co-morbidities and 
previous CSU medications] were collected from the time 
of omalizumab/ciclosporin initiation.
The UAS7 is a validated patient reported scoring sys-
tem [1], which assesses intensity of pruritus (0 =  none; 
1  =  mild; 2  =  moderate; 3  =  intense) and number of 
wheals (0 = none; 1 = 1–20 wheals; 2 = 20–50 wheals; 
3  =  50+ wheals or large confluent areas of wheals) 
over 24  h. Daily UAS scores (range 0–6 points/day) are 
summed over 7  days to create the weekly UAS7 (range 
0–42), with higher scores reflecting higher disease 
activity. The DLQI is a patient-reported validated ques-
tionnaire [11] which measures the health-related qual-
ity of life (QoL) of adults suffering from a skin disease 
(range 0–30), with higher scores meaning greater QoL 
impairment.
Dosing patterns of omalizumab/ciclosporin, outcomes 
(routinely-administered UAS7, DLQI scores, clinician’s 
assessments of symptom resolution and adverse events) 
were collected from the date of omalizumab/ciclosporin 
initiation to the date of data collection, irrespective of the 
treatment duration. Disease response according to clini-
cian’s assessment documented in the medical record was 
classified as either ‘clear of symptoms’, ‘improved symp-
toms’ or ‘non-responder’ (including patients with no 
change or worsening of CSU); the best response docu-
mented during treatment was recorded as the study out-
come measure. Adverse events were extracted from the 
hospital case notes and patient correspondence (primary 
care notes were not available). The date, severity, serious-
ness and assessment of causality of each adverse event 
were recorded using a consistent set of coded response 
options.
Analyses were conducted with the available data and 
the number available for each analysis is stated where 
data were absent from the clinical record; no imputation 
of missing data was undertaken.
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Results
Patients
The baseline characteristics of the patients included in 
the omalizumab and ciclosporin studies are presented 
in Table 1. In the omalizumab study, of the 46 patients 
with CSU (mean age 43.3 years; SD 13.1), 36 (78%) were 
female. Thirty-six (78%) patients had CSU and 10 (22%) 
had CSU concurrent with chronic inducible urticaria 
(CIndU; 7 pressure urticaria, 3 dermographism); four 
also had documented features of urticarial vasculitis 
(UV). Angioedema was recorded for 38 (83%) patients; 
31 (86%) of those with CSU only and 7 (70%) of those 
with CSU + CIndU (see Table 1). The ciclosporin study 
included 72 patients with CSU (mean age 40.5  years; 
SD 12.8), of whom 61 (85%) were female. Among these, 
66 (92%) had a diagnosis of CSU only, while 6 (8%) had 
CSU  +  CIndU (three dermographism, two delayed 
pressure urticaria, one symptomatic dermographism/
delayed pressure urticaria and aquagenic pruritus). Fifty 
patients (69%) had a recorded history of angioedema 
(see Table 1).
Dosing
Twenty-four (52%) omalizumab-treated patients were 
initiated on 150 mg and 20 (43%) on 300 mg omalizumab. 
Eight (17%) patients increased the dose from 150 mg to 
a maximum of 300  mg and 4 (9%) patients reduced the 
dose from 300 mg. Dosing frequency was 4 weekly in 32 
patients, 3 weekly in one patient, 2 weekly in six patients 
and >4 weekly in six patients (one patient received only 
one dose). Omalizumab treatment had been discontin-
ued in 20 patients (43%) at the time of data collection; the 
reasons for withdrawal were not documented.
The median (range) duration of ciclosporin treatment 
was 4.8 (0.2–67.1) months overall, 4.4 (0.2–67.1) months 
for complete courses and 28.1 (17.3–38.6) months for 
ongoing courses at data collection. The mean daily dose 
of ciclosporin was 174  mg (SD 85.6). The dose in mg/
kg could be calculated for 37 patients; 3 mg/kg was the 
most common starting dose [8/37 patients (22%)] and 
4  mg/kg was the most common maximum dose [10/37 
patients (27%)]. During ciclosporin therapy, 27 (38%) 
patients remained on a constant dose, 15 (21%) increased 
dose, 13 (18%) decreased dose, 7 (10%) increased then 
decreased dose, 4 (6%) decreased then increased dose 
and 6 (8%) had other patterns of dose changes. Ciclo-
sporin had been discontinued in 67 (93%) patients at the 
time of data collection, with 25 (35%) stopping within 
3  months of initiation. Reasons for ciclosporin with-
drawal were given for 49/67 (73%) patients, indicating 
lack of benefit in 23/49 patients (46%), intolerance in 
13/49 (26%), successful treatment in 11/49 (22%) and 
other reasons in 3 (6%).
Treatment response
Omalizumab study
Clinician-documented comments on the best response 
to omalizumab treatment were available for 36 (78%) 
patients, of whom 15 (42%) were clear of symptoms, 
12 (33%) had some improvement and 9 (25%) had not 
responded.
The UAS7 score was available for 27 patients at base-
line [mean weekly UAS7 27.5 (SD 10.4)]. UAS7 was avail-
able for 28 patients at some time following omalizumab 
initiation [mean UAS7 3.1 (SD 6.3)], and of these 19 
(68%) achieved a score of 0 (itch/hives free). The mean 
weekly UAS7 score for 19 patients with UAS7 recorded 
at 3  months (±1  month) following omalizumab initia-
tion was 5.8 (SD 9.8). In the 22 patients with paired UAS7 
scores, the mean weekly score decreased by 25.4 (SD 
12.5) points (P  <  0.0001, paired t test) following omali-
zumab initiation, as shown in Figure 1. The mean of the 
patients’ percentage improvements was 85%. A reduction 
in UAS7 score of at least 75% from baseline was observed 
in 17/22 (77%) patients and a reduction of at least 90% in 
15/22 (68%), see Figure 2.
The impact of CSU on QoL was measured using the 
DLQI in 32 patients at baseline [mean score 19.5 (SD 
5.2)]. DLQI was available in 31 patients at some time 
during omalizumab treatment [mean score 3.2 (SD 5.2)], 
and of these 20 (65%) achieved a DLQI score of 0–1 (no 
impact of disease on QoL). In the 28 patients with paired 
scores, the mean DLQI score decreased by 16.4 (SD 9.1) 
points (P  <  0.0001, paired t test) following omalizumab 
initiation, as shown in Figure 3. The mean of the patients’ 
percentage improvements was 80%. An improvement 
of at least 75% in DLQI was observed in 22/28 (79%) 
patients and an improvement of at least 90% in 18/28 
(64%; see Figure 2).
Ciclosporin study
The best response to ciclosporin according to clinician-
documented comments [available for 60 (83%) patients] 
was clear of symptoms in 10 (17%), improved in 33 (55%) 
and no response in 17 (28%) patients. The UAS7 score 
was not used to assess response to ciclosporin.
DLQI was measured in 20 patients at baseline [mean 
score 17.4 (SD 6.6)]. DLQI score was available at some 
time during ciclosporin treatment in 19 patients [mean 
score 8.5 (SD 7.3)], and of these 4 (21%) achieved a 
DLQI score of 0–1. In the 17 patients with paired DLQI 
scores, mean score decreased by 8.9 (SD 9.2) points 
(P  =  0.0005, paired t test), as shown in Figure  4. The 
mean of the patients’ percentage improvements was 45%. 
An improvement in DLQI of at least 75% was observed in 
7/17 (41%) patients and an improvement of at least 90% 
in 3/17 (18%; see Figure 2).
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Table 1 Baseline patient and disease characteristics
Omalizumab study, N = 46  
(unless otherwise stated)
Ciclosporin study, N = 72 
(unless otherwise stated)
Sex
 Male 10 (22%) 11 (15%)
 Female 36 (78%) 61 (85%)
Age (years)
 <20 0 3 (4%)
 20–29 10 (22%) 12 (17%)
 30–39 6 (13%) 16 (22%)
 40–49 16 (35%) 28 (39%)
 50–59 8 (17%) 7 (10%)
 60–69 5 (11%) 4 (6%)
 70–79 1 (2%) 2 (3%)
 Mean (SD) 43.3 (13.1) 40.5 (12.8)
Weight (kg) n = 21 n = 24
 Mean (SD) 85.3 (27.1) 78.8 (16.2)
Diagnosis
 CSU only 36 (78%)a 66 (92%)
 CSU + CIndU 10 (22%)a 6 (8%)
History of angioedema
 All patients 38 (83%) 50 (69%)
 CSU only 31 (86%) 45 (68%)
 CSU + CIndU 7 (70%) 5 (83%)
Co‑morbidities (not mutually exclusive)
 None 13 (28%) 43 (60%)
 Allergic condition 9 (20%) 10 (14%)
 Hypertension 8 (17%) 6 (8%)
 Asthma 7 (15%) 0c
 Eczema 7 (15%) 0c
 Thyroid disorder 3 (7%) 2 (3%)
 Depression 5 (11%) 4 (6%)
 Anxiety 1 (2%) 4 (6%)
 Other 17 (37%)b 16 (22%)b
Time since first symptoms (years) N = 42 N = 57
 <1 0 12 (21%)
 1 < 5 15 (36%) 25 (44%)
 5 < 10 16 (38%) 10 (18%)
 ≥10 11 (26%) 10 (18%)
 Not recorded 4 15
 Median (IQR) 7.2 (3.7–10.0) 3.2 (1.5–7.6)
Time since diagnosis (years) N = 37 N = 51
 <0.5 0 31 (61%)
 0.5 < 1 6 (16%) 11 (22%)
 1 < 5 17 (46%) 9 (18%)
 5 < 10 12 (32%) 0
 ≥10 2 (5%) 0
 Not recorded 9 21
 Median (IQR) 3.8 (1.2–7.5) years 3.7 (2.3–9.1) months
Previous 2nd/3rd line CSU medications (not mutually exclusive)
 2nd line
  Montelukast 23 (50%) 19 (16%)
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Adverse events
Omalizumab study
Potential adverse events were documented during omali-
zumab treatment for 17 (37%) patients, with a total of 
36 events (Table  2). The most common adverse events 
recorded were skin reactions (eight reports from four 
patients), angioedema (six reports from three patients), 
and ‘anaphylaxis’ (three reports from two patients). 
Overall 35 events were clinician-assessed for severity and 
causal relationship with omalizumab and judged to be 
mild in 10 (29%), moderate in 19 (54%) severe in 4 (11%) 
or not applicable (pregnancy) in 2 (6%). A possible causal 
Only data that were recorded in the notes are included so the totals for each field are different for most characteristics.
a Two patients showed features of urticarial vasculitis (UV) during their recorded medical history.
b Other co-morbidities (not specified in the study DCF) in omalizumab study patients were: Diabetes, 3; Chronic fatigue, 2; Obesity, 2; PVD, 2; osteoporosis/
osteopenia, 2; COPD, inflammatory bowel disease, adrenal insufficiency, cardiovascular disease, renal transplant, haemophilia, sarcoidosis, inflammatory arthritis (×1 
each). Other co-morbidities (not specified in the study DCF) in ciclosporin study patients were: Diabetes, 4; Autoimmune disorder, 3; Cardiovascular disease, 2 and IBS, 
Ovarian cysts/fibroids, Cancer, COPD, Chronic fatigue syndrome, pancreatitis, mastitis, stroke/TIA, PE, gall stones, sinusitis and facial nerve palsy (×1 each).
c Patients with asthma or eczema were excluded from the ciclosporin study.
Table 1 continued
Omalizumab study, N = 46  
(unless otherwise stated)
Ciclosporin study, N = 72 
(unless otherwise stated)
  Dapsone 12 (26%) 3 (4%)
  H2‑antihistamine 10 (22%) 8 (11%)
  Sulphasalazine 7 (15%) 1 (1%)
  Hydroxychloroquine 8 (17%) 1 (1%)
 3rd line
  Ciclosporin 33 (72%) –
  Omalizumab – 0
  Methotrexate 17 (37%) 1 (1%)
  Azathioprine 15 (33%) 4 (6%)
  Mycophenolate mofetil 12 (26%) 2 (3%)
  Tacrolimus 2 (4%) 0
  Any 3rd line 39 (85%) 7 (10%)
 Others
  UVB light therapy 1 (2%) 0
  Rituximab 1 (2%) 0
  Cyclophosphamide 1 (2%) 0
  Colchicine 3 (7%) 0
  Antidepressant 12 (26%) 6 (8%)
  Corticosteroids in previous 12 months 29 (74%) (n = 39) 18 (29%) (n = 63)
CSU severity and QoL
 UAS7 Score n = 27
  0 0 –
  1–6 (well controlled) 1 (4%) –
  7–15 (mild disease) 2 (7%) –
  16–27 (moderate disease) 10 (37%) –
  28–42 (severe disease) 14 (52%) –
  Mean (SD) 27.5 (10.4) –
  Median (IQR) 29.0 (20.7–36.1) –
 DLQI Score n = 32 n = 20
  0–1 (disease no impact on QoL) 0 0
  2–5 (small impact) 3 (9%) 0
  6–10 (moderate impact) 1 (3%) 1 (5%)
  11–20 (large impact) 9 (28%) 13 (65%)
  21–30 (extremely large impact) 19 (59%) 6 (30%)
  Mean (SD) 19.5 (7.1) 17.4 (6.6)
  Median (IQR) 21.5 (15.0–24.0) 16.5 (12.0–22.0)
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relationship with omalizumab was recorded in 20 (57%), 
with 6 (17%) unrelated and 9 (26%) unknown. Episodes 
of anaphylaxis were reviewed in detail. One episode of 
‘anaphylaxis’ was clinician-rated as ‘moderate’ in sever-
ity, and ‘possibly related’ to omalizumab. The episode 
occurred 2.5  h after omalizumab administration and 
involved shortness of breath, tongue angioedema and 
urticaria (blood pressure and pulse were normal, tryptase 
was not measured), which responded to oxygen, antihis-
tamine, hydrocortisone and self-administered adrenaline 
in 15 min and the patient was not admitted to hospital. 
A second episode in the same patient also occurred on 
the day of omalizumab dosing and was clinician-rated 
as ‘severe’ and ‘possibly related’ to omalizumab. On this 
occasion the patient was admitted to hospital overnight; 
tryptase was slightly raised at 15.5  ng/ml acutely (nor-
mal < 11.4 ng/ml) and 13.4 ng/ml the next day. Although 
both episodes in this patient were documented as ‘pos-
sibly related’ to omalizumab, the patient had a history of 
complex and severe CSU, including recurrent ‘anaphy-
laxis’ prior to omalizumab, which was incompletely con-
trolled by the therapy. In our opinion the two episodes 
of ‘anaphylaxis’ in this patient were most likely to have 
been an exacerbation of the underlying CSU. The third 
episode of reported anaphylaxis, in a different patient, 
also occurred on the day of omalizumab injection, and 
was clinician-rated as ‘severe’. However, we consider this 
episode not to be consistent with anaphylaxis, although 
Figure 1 Omalizumab response: within‑patient paired UAS7 scores at baseline and lowest recorded on treatment.
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Figure 2 Proportions of patients with 75 and 90% improvement in UAS7 and DLQI from baseline.
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possibly related to omalizumab, based on reviewing the 
case in detail (symptoms: sharp joint pains and nausea, 
without severe shortness of breath, hypotension, hives or 
angioedema; treated by hospital admission for fluids and 
hydrocortisone). Omalizumab treatment was continued 
in all three cases.
Ciclosporin study
Potential adverse events were documented during ciclo-
sporin treatment for 28 (39%) patients, with 49 episodes 
(Table  2). The most commonly reported adverse events 
were hypertension (eight reports), fatigue/tiredness (six 
reports), gastrointestinal problems (four reports) and 
headache (four reports). Of the 49 events, 45 were clini-
cian-assessed for severity, with 24 (53%) rated mild, 16 
(36%) moderate, 3 (7%) severe and 2 (4%) not applicable 
(pregnancy). Thirty (61%) were judged ‘possibly related’ 
to ciclosporin, 4 (8%) unrelated and 15 (31%) unknown.
Discussion
These two real world multicentre retrospective observa-
tional studies of the treatment of CSU, with either ciclo-
sporin or omalizumab, were carried out in patients for 
whom early treatment options had failed. The patients 
Figure 3 Omalizumab response: within‑patient paired DLQI scores at baseline and lowest recorded on treatment.
Figure 4 Ciclosporin response: within‑patient paired DLQI scores at baseline and lowest recorded on treatment.
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Table 2 Adverse events
a The number of patients reporting an AE is not the total in this column because some patients experienced more than one adverse event symptom.
AE symptom (not mutually exclusive) No. symptoms reported No. patients
Omalizumab N = 17a
 Skin (rash, erythema, wheals, eczema, urticaria/itching) 8 4
 Angioedema 6 3
 Anaphylaxis 3 2
 Headaches 2 2
 Hot/flushed 2 2
 Omalizumab reaction (not specified) 1 1
 Palpitations 2 2
 Pregnancy 2 2
 ”Fuzzy head” 1 1
 Biliary colic 1 1
 Conjunctival haemorrhage 1 1
 Erectile dysfunction 1 1
 Hair loss 1 1
 Injection site reaction 1 1
 Sinus bradycardia 1 1
 Shortness of breath 1 1
 Tachycardia 1 1
 Type III Immune complex medicine reaction 1 1
 Total—omalizumab 36 –
Ciclosporin N = 28a
 Hypertension 8 8
 Fatigue/tiredness 6 6
 GI 4 4
 Headaches 4 4
 Altered sensation 3 2
 Pregnancy 2 2
 Worsening renal function 2 2
 Dizziness/collapse 2 2
 Excess hair growth 1 1
 Increased ESR 1 1
 Lower back pain 1 1
 Loin pain 1 1
 Lumpectomy 1 1
 Memory problems 1 1
 Miscarriage 1 1
 Muscle weakness 1 1
 Side effects 1 1
 UTI 1 1
 Peripheral oedema 1 1
 Poor wound healing 1 1
 Mild stroke 1 1
 Urticarial flare 1 1
 Gum soreness and swelling 1 1
 Unwell 1 1
 Visual disturbance 1 1
 Seborrheic keratosis 1 1
 Total—ciclosporin 49 –
Page 9 of 11Savic et al. All Asth Clin Immun  (2015) 11:21 
were similar in the two studies with respect to age and 
gender distributions and consistent with the wider pop-
ulation of patients with CSU [12] and patients included 
in clinical trials of omalizumab [7–9]. The recorded 
prevalence of unsolicited psychiatric co-morbidities was 
much lower in both studies than the 30–50% reported 
elsewhere in patients with CSU [13, 14]. This disparity is 
possibly due to incomplete recording of psychiatric mor-
bidity and could suggest that this co-morbidity is under-
assessed in CSU care in routine practice.
There was considerable variability in initial ciclosporin 
dosing in the present study and reasons for dose changes 
were not recorded. Guidelines do not recommend a dose 
of ciclosporin in CSU but initiating patients on a low 
dose and up-titrating is an approach that has been advo-
cated to minimise adverse effects while preserving effi-
cacy [15]. Alternatively, studies have used doses of up to 
4 mg/kg [16], with 3 mg/kg commonly reported as being 
effective and tolerable [17] even for long periods [18]. 
Staged dose reductions from starting doses of 3–4 mg/kg 
are standard dermatology clinical practice in response to 
adverse effects. The approach to ciclosporin dosing in the 
present study (either starting high or starting low) varied 
between centres rather than between individual patients 
and seemed to reflect clinician preference.
Due to the absence of any disease severity scores for 
ciclosporin-treated patients the baseline severity of CSU 
in the two studies cannot be directly compared, although 
DLQI, which has been shown to correlate well with 
UAS7 in patients with CSU [19] was similar at baseline 
for patients in the two studies. The omalizumab-treated 
patients in the present study appeared to be characteris-
tic of a more severe disease group as concurrent CSU and 
CIndU was more prevalent, angioedema more frequent, 
and more patients had co-morbidities compared with 
the ciclosporin-treated patients. However, we acknowl-
edge that this may reflect more thorough documentation 
of medical history in order to obtain omalizumab fund-
ing. Omalizumab was also initiated later after initial CSU 
diagnosis than ciclosporin and most omalizumab-treated 
patients had tried, and were refractory to, third-line 
immunosuppressants (Table 1), reflecting the unlicensed 
status and restricted funding of omalizumab for CSU in 
the studied period. Thus it is likely that a more severe 
group was measured in the omalizumab study and as a 
consequence, direct comparisons of outcomes between 
the studies of omalizumab and ciclosporin are not 
possible.
Although formal direct comparison of treatment 
outcomes is not possible, we can infer some aspects 
of effectiveness based on the similar baseline DLQI 
in both groups. The observed improvement in mean 
DLQI appeared to be greater in patients treated with 
omalizumab compared with ciclosporin-treated patients, 
with considerably more omalizumab-treated patients 
achieving a 75% reduction in DLQI compared with ciclo-
sporin-treated patients (79 and 41%, respectively). The 
difference was even greater (65 and 18% respectively) in 
the proportions achieving a 90% reduction in DLQI.
Documented clinicians’ comments were a more widely-
available assessment of response to treatment. When 
reported responses were evaluated categorised as ‘clear 
of symptoms’, ‘improved symptoms’ or ‘no response’, the 
data suggested that the response was more often com-
plete, meeting the recommended goal of CSU treatment 
[1] with omalizumab treatment (42% ‘clear of symptoms’) 
than with ciclosporin treatment (17% ‘clear of symp-
toms’). However, caution needs to be exerted in inter-
pretation of these comments due to the subjective nature 
of the data, and we advocate use of systematic, validated 
measures of disease severity for all patients with CSU to 
help clinical teams to monitor optimal disease control 
by providing consistent outcomes for each treatment 
prescribed.
Further evidence of the effectiveness of omalizumab in 
this severely affected cohort was available from patient-
reported changes in disease severity (UAS7), with over 
three quarters (77%) of evaluable omalizumab-treated 
patients achieving a 75% reduction in UAS7 score and 
68% achieving a UAS7 score of 0 (itch and hives free). As 
this retrospective study was dependent on the routine 
schedule of clinic visits and clinical practice with respect 
to formal disease assessment, the data do not allow anal-
ysis of the speed of response to omalizumab as the pro-
portion of patients with UAS7 scores even at 3  months 
was small. However, data from Phase III trials [7–9] and 
observational studies [20, 21] indicate that responses are 
rapid, being seen in 53–57% of cases 1 week after the first 
injection of omalizumab. Although UAS7 was not used 
to monitor efficacy of ciclosporin treatment, it is notable 
that 46% of 50 reasons given for stopping ciclosporin in 
49 patients, were related to lack of efficacy.
Tolerability appears similar for both drugs, as the over-
all proportions of patients with documented adverse 
events were similar (37 and 39% for omalizumab and 
ciclosporin respectively). There was a broader range of 
adverse events associated with ciclosporin than with 
omalizumab and the ciclosporin adverse events reflected 
its known safety profile. It is notable that many adverse 
events recorded during omalizumab treatment closely 
resemble the symptoms of CSU itself, exemplified by 
the patient with two reported episodes of ‘anaphylaxis’ 
following omalizumab dosing, which were difficult to 
separate from the prior history of ‘anaphylaxis’ which 
was a feature of the CSU in that individual. This obser-
vation highlights the difficulty in differentiating natural 
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fluctuations in disease symptoms from adverse events 
when retrospectively interpreting medical records 
originally made for clinical care rather than for medical 
research. As these were small retrospective observational 
studies and formal recording of adverse events was not 
of the same standard as required by prospective trials, 
these data need to be interpreted with caution in associa-
tion with the broader evidence of tolerability and safety 
of both drugs.
Conclusions
It is clear from the present real world data that both 
omalizumab and ciclosporin treatment were associated 
with a significant improvement in QoL in patients with 
CSU. Recently updated European guidelines recommend 
both ciclosporin and omalizumab as 3rd line CSU treat-
ment options [1]. However, data from these two small 
real world studies indicate a greater proportion of omal-
izumab-treated patients achieved at least a 75 and 90% 
improvement in DLQI compared with ciclosporin-treated 
patients, suggesting omalizumab treatment is more effec-
tive in improving patient QoL. The clinician-documented 
assessment of response to treatment suggested that more 
omalizumab-treated than ciclosporin-treated patients 
achieved clearance of symptoms. Omalizumab was asso-
ciated with a significant reduction in disease activity in 
line with findings from recently published Phase III stud-
ies and case series [7–9, 19, 20]. The results of these two 
retrospective observational studies were not directly com-
parable due to differences between the patient cohorts 
and lack of consistently recorded validated measures of 
disease. Adoption of a uniform approach to documenta-
tion of CSU disease severity at regular time points, using 
validated tools, would facilitate comparison of different 
treatment options and provide evidence for the optimum 
management of patients with CSU. Despite the limita-
tions of the studies reported here, in the absence of larger 
prospective studies, these real world data will be benefi-
cial for clinicians in making informed decisions between 
third-line treatment options for CSU until stronger evi-
dence becomes available.
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